Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Efficacy of DMSA Therapy in a Sample of Arab Children with Autistic Spectrum Disorder.

Blaucok-Busch E, Amin OR, Dessoki HH, Rabah T.

Maedica (Buchar). 2012 Sep;7(3):214-21.

2.
3.

Toxic Metals and Essential Elements in Hair and Severity of Symptoms among Children with Autism.

Blaurock-Busch E, Amin OR, Dessoki HH, Rabah T.

Maedica (Buchar). 2012 Jan;7(1):38-48.

4.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J.

BMC Clin Pharmacol. 2009 Oct 23;9:17. doi: 10.1186/1472-6904-9-17.

5.

Modeling clinical outcome of children with autistic spectrum disorders.

Coplan J, Jawad AF.

Pediatrics. 2005 Jul;116(1):117-22.

PMID:
15995041
6.

24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study.

Soden SE, Lowry JA, Garrison CB, Wasserman GS.

Clin Toxicol (Phila). 2007 Jun-Aug;45(5):476-81.

PMID:
17503250
7.

Comparison of parental stress among mothers and fathers of children with autistic spectrum disorder in Iran.

Soltanifar A, Akbarzadeh F, Moharreri F, Soltanifar A, Ebrahimi A, Mokhber N, Minoocherhr A, Ali Naqvi SS.

Iran J Nurs Midwifery Res. 2015 Jan-Feb;20(1):93-8.

8.

Heavy metals and trace elements in hair samples of autistic children in central Saudi Arabia.

Al-Ayadhi LY.

Neurosciences (Riyadh). 2005 Jul;10(3):213-8.

PMID:
22473261
9.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J.

BMC Clin Pharmacol. 2009 Oct 23;9:16. doi: 10.1186/1472-6904-9-16.

10.

Broader Autism Phenotype in Iranian Parents of Children with Autism Spectrum Disorders vs. Normal Children.

Mohammadi MR, Zarafshan H, Ghasempour S.

Iran J Psychiatry. 2012 Fall;7(4):157-63.

11.

Diagnostic chelation challenge with DMSA: a biomarker of long-term mercury exposure?

Frumkin H, Manning CC, Williams PL, Sanders A, Taylor BB, Pierce M, Elon L, Hertzberg VS.

Environ Health Perspect. 2001 Feb;109(2):167-71.

12.

Hair toxic metal concentrations and autism spectrum disorder severity in young children.

Geier DA, Kern JK, King PG, Sykes LK, Geier MR.

Int J Environ Res Public Health. 2012 Dec 6;9(12):4486-97. doi: 10.3390/ijerph9124486.

13.

A key role for an impaired detoxification mechanism in the etiology and severity of autism spectrum disorders.

Alabdali A, Al-Ayadhi L, El-Ansary A.

Behav Brain Funct. 2014 Apr 28;10:14. doi: 10.1186/1744-9081-10-14.

14.

Autism: a form of lead and mercury toxicity.

Yassa HA.

Environ Toxicol Pharmacol. 2014 Nov;38(3):1016-24. doi: 10.1016/j.etap.2014.10.005. Epub 2014 Nov 6.

PMID:
25461563
15.

Olfactory functions are not associated with autism severity in autism spectrum disorders.

Dudova I, Hrdlicka M.

Neuropsychiatr Dis Treat. 2013;9:1847-51. doi: 10.2147/NDT.S54893. Epub 2013 Nov 27.

16.

Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006.

Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2009 Dec 18;58(10):1-20. Erratum in: MMWR Surveill Summ. 2010 Aug 6;59(30):956.

17.

Metal exposure in the physically and mentally challenged children of Punjab, India.

Blaurock-Busch E, Friedle A, Godfrey M, Schulte-Uebbing CE.

Maedica (Buchar). 2010 Apr;5(2):102-10.

18.

A Randomized, Placebo-controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders.

Saad K, Eltayeb AA, Mohamad IL, Al-Atram AA, Elserogy Y, Bjørklund G, El-Houfey AA, Nicholson B.

Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):188-93. doi: 10.9758/cpn.2015.13.2.188.

19.

Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.

Akhondzadeh S, Erfani S, Mohammadi MR, Tehrani-Doost M, Amini H, Gudarzi SS, Yasamy MT.

J Clin Pharm Ther. 2004 Apr;29(2):145-50.

PMID:
15068403
20.

[Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form].

Desjardins S, Doyen C, Contejean Y, Kaye K, Paubel P.

Encephale. 2009 Apr;35(2):168-72. doi: 10.1016/j.encep.2008.01.004. Epub 2008 Jul 7. French.

PMID:
19393386
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk